ReviewCNS & neurological disorders drug targets2024

Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease.

Erwan Bezard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.